The influence of GC therapy on QOL for metastatic and recurrent invasive urothelial carcinoma

The influence of GC therapy on QOL for metastatic and recurrent invasive urothelial carcinoma - The influence of GC therapy on QOL for invasive urothelial carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030160

Enrollment

Registered

2018-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial carcinoma

Interventions

Gemcitabine is administarrated 3 times for 3 weeks. Cisplatine is administrated 1 time. This is 1 cycle and we undergo 3 cycles. So, time of administration is 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with metastatic or recurrent invasive urothelial carcinoma who are able to receive GC therapy

Exclusion criteria

Exclusion criteria: The patients who are not able to receive GC therapy

Design outcomes

Primary

Measure	Time frame
QOL	—

Secondary

Measure	Time frame
Adverse events Anti-cancer effect	—

Countries

Japan

Contacts

Public ContactEIji Kikuchi

Keio University School of Medicine Department of Urology

eiji-k@kb3.so-net.ne.jp03-5363-3825

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026